<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043051</url>
  </required_header>
  <id_info>
    <org_study_id>13705</org_study_id>
    <secondary_id>2R01HL128393-04</secondary_id>
    <nct_id>NCT05043051</nct_id>
  </id_info>
  <brief_title>Autoimmune Basis for Postural Tachycardia Syndrome</brief_title>
  <official_title>Autoimmune Basis for Postural Tachycardia Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that an antibody-mediated autoimmune&#xD;
      reaction will cause symptoms of autonomic dysfunction in some patients with postural&#xD;
      tachycardia syndrome (POTS). The investigators further hypothesize that electrical&#xD;
      stimulation of the vagus nerve will improve POTS symptoms, autoimmunity and inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is designed to test the hypothesis that muscarinic autoantibody-mediated&#xD;
      parasympathetic dysfunction contributes to the pathogenesis of POTS, and that parasympathetic&#xD;
      (vagal) stimulation improves POTS symptoms, autoimmunity and inflammation.&#xD;
&#xD;
      Define and determine the prevalence, burden, and clinical significance of muscarinic&#xD;
      autoantibodies in a well-phenotyped cohort of POTS patients with and without gastroparesis&#xD;
      and a matched cohort of healthy control subjects.&#xD;
&#xD;
      Evaluate the impact of vagal stimulation on antibody suppression, inflammatory inhibition,&#xD;
      and symptom improvement in POTS patients. Non-invasive transcutaneous stimulation of the&#xD;
      auricular branch of the vagus nerve (tragus stimulation) will be used to increase&#xD;
      parasympathetic activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>5 minute</time_frame>
    <description>Average of heart rate variability during the posture test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Postural Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>Vagal stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vagal stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the tragus for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the earlobe for 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vagal stimulation</intervention_name>
    <description>Vagal stimulation</description>
    <arm_group_label>Vagal stimulation</arm_group_label>
    <other_name>Transcutaneous electrical nerve stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham stimulation</intervention_name>
    <description>Sham vagal stimulation</description>
    <arm_group_label>Sham stimulation</arm_group_label>
    <other_name>Transcutaneous electrical nerve stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years old, female or male&#xD;
&#xD;
          -  Either healthy control or individual with postural tachycardia syndrome (POTS) defined&#xD;
             as heart rate increase &gt;30 bpm from supine within 10 min of standing, in the absence&#xD;
             of orthostatic hypotension (&gt;20/10 mmHg fall in blood pressure), with chronic symptoms&#xD;
             (&gt;6 months), and in the absence of other acute cause of orthostatic tachycardia&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
          -  Understand and be able to comply with the study procedures and restrictions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertension (&gt;150 mmHg systolic and &gt;100 mmHg diastolic) based on history or findings&#xD;
             at screening&#xD;
&#xD;
          -  Orthostatic hypotension (consistent drop in blood pressure &gt;20/10 mmHg with 10 min of&#xD;
             standing)&#xD;
&#xD;
          -  Cardiovascular disease, such as myocardial infarction within 6 months&#xD;
&#xD;
          -  History or presence of significant immunological or hematological disorders&#xD;
&#xD;
          -  History of vagotomy&#xD;
&#xD;
          -  Currently pregnant women or women planning on becoming pregnant â‰¤ 3 months&#xD;
&#xD;
          -  Inability to comply with the protocol&#xD;
&#xD;
          -  Patients with active implants (such as a cardiac pacemaker, or a cochlear implant)&#xD;
&#xD;
        Healthy control subjects will be healthy, non-smoking and on no chronic medications at the&#xD;
        time of the study. Healthy control subjects will be group-matched to the POTS patients for&#xD;
        age and gender.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stavros Stavrakis, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xichun Yu</last_name>
    <phone>405-271-5896</phone>
    <phone_ext>47779</phone_ext>
    <email>xichun-yu@ouhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brittany Karfonta</last_name>
    <phone>405-271-3480</phone>
    <phone_ext>34889</phone_ext>
    <email>Brittany-Karfonta@ouhsc.edu</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POTS</keyword>
  <keyword>Vagal Stimulation</keyword>
  <keyword>Autoantibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

